Skip to main content
Clinical Trials/CTRI/2024/07/070880
CTRI/2024/07/070880
Not yet recruiting
未知

A collaborative network on respiratory disease epidemiology in India and capacity building - RespIND-Net

Society For Applied Studies0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Society For Applied Studies
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Live birth
  • 2\.Available for enrolment within 14 days of birth
  • 3\.Family planning to stay in the study area until 2 years after childbirth
  • 4\.Parental consent for participation of their child
  • 1\.Under\-five children hospitalized for following respiratory infection symptoms, cough, shortness of breath with RR more than 60 for infant below 2 months, more than 50 for infants 2\-12 months and more than 40 for children above 1 year, onset within the past 10 days
  • 2\.Contact at 90 days after discharge is feasible
  • 3\.Additional criteria for infants 0\-6 months age, Apnoea, Sepsis, fever (more than equal to 37\.5°C) or hypothermia (less than 35\.5°C), shock (lethargy, fast breathing, cold skin, prolonged capillary refill, or fast weak pulse), seriously ill with no apparent cause
  • 4\.Parental consent for participation of their child

Exclusion Criteria

  • 1\.Twins or triplets
  • 2\.Documented birth weight under 1500 grams or weight under 1500 grams at enrolment
  • 3\.Gestational age less than 32 weeks
  • 4\.HIV positive or born to women with known HIV infection
  • For Tier 2:
  • 1\.Presenting complaints/diagnosis for hospitalization are non\-respiratory
  • 2\.Respiratory infection is healthcare associated i.e. presenting complaints of cough or shortness of breath began 48 hours after admission.
  • 3\.Diagnosed case of HIV or primary immunodeficiency
  • 4\.Children receiving chemotherapy or immunomodulator therapy
  • 5\.Children with major congenital anomalies affecting the cardiovascular, neural and respiratory system

Outcomes

Primary Outcomes

Not specified

Similar Trials